Advertisement

Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial

Published:December 26, 2017DOI:https://doi.org/10.1016/j.biopsych.2017.12.006

      Abstract

      Background

      Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine.

      Methods

      We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that had been stabilized with clozapine were allocated into three groups for 6 weeks’ add-on treatment of 1 g/day sodium benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and Global Assessment of Functioning. Side effects and cognitive functions were also measured.

      Results

      Both doses of sodium benzoate produced better improvement than placebo in the Scale for the Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group.

      Conclusions

      Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant schizophrenia. Further studies are warranted to elucidate the optimal dose and treatment duration as well as the mechanisms of sodium benzoate for clozapine-resistant schizophrenia.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lao K.S.J.
        • Tam A.W.Y.
        • Wong I.C.K.
        • Besag F.M.C.
        • Man K.K.C.
        • Chui C.S.L.
        • et al.
        Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups.
        Pharmacoepidemiol Drug Saf. 2017; 26: 1387-1394
        • Kane J.M.
        • Correll C.U.
        The role of clozapine in treatment-resistant schizophrenia.
        JAMA Psychiatry. 2016; 73: 187-188
        • Heaton R.K.
        • Gladsjo J.A.
        • Palmer B.W.
        • Kuck J.
        • Marcotte T.D.
        • Jeste D.V.
        Stability and course of neuropsychological deficits in schizophrenia.
        Arch Gen Psychiatry. 2001; 58: 24-32
        • Lin C.H.
        • Huang C.L.
        • Chang Y.C.
        • Chen P.W.
        • Lin C.Y.
        • Tsai G.E.
        • et al.
        Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia.
        Schizophr Res. 2013; 146: 231-237
        • Kane J.
        • Honigfeld G.
        • Singer J.
        • Meltzer H.
        Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
        Arch Gen Psychiatry. 1988; 45: 789-796
        • Conley R.R.
        • Kelly D.L.
        Management of treatment resistance in schizophrenia.
        Biol Psychiatry. 2001; 50: 898-911
        • Samara M.T.
        • Dold M.
        • Gianatsi M.
        • Nikolakopoulou A.
        • Helfer B.
        • Salanti G.
        • et al.
        Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis.
        JAMA Psychiatry. 2016; 73: 199-210
        • Leucht S.
        • Cipriani A.
        • Spineli L.
        • Mavridis D.
        • Orey D.
        • Richter F.
        • et al.
        Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis.
        Lancet. 2013; 382: 951-962
        • Miyamoto S.
        • Jarskog L.F.
        • Fleischhacker W.W.
        Schizophrenia: When clozapine fails.
        Curr Opin Psychiatry. 2015; 28: 243-248
        • Sommer I.E.
        • Begemann M.J.
        • Temmerman A.
        • Leucht S.
        Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review.
        Schizophr Bull. 2012; 38: 1003-1011
        • Porcelli S.
        • Balzarro B.
        • Serretti A.
        Clozapine resistance: Augmentation strategies.
        Eur Neuropsychopharmacol. 2012; 22: 165-182
        • Veerman S.R.
        • Schulte P.F.
        • Begemann M.J.
        • Engelsbel F.
        • de Haan L.
        Clozapine augmented with glutamate modulators in refractory schizophrenia: A review and metaanalysis.
        Pharmacopsychiatry. 2014; 47: 185-194
        • Gray L.
        • van den Buuse M.
        • Scarr E.
        • Dean B.
        • Hannan A.J.
        Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: Association with N-methyl-D-aspartic acid receptor up-regulation.
        Int J Neuropsychomharmacol. 2009; 12: 45-60
        • Schwieler L.
        • Linderholm K.R.
        • Nilsson-Todd L.K.
        • Erhardt S.
        • Engberg G.
        Clozapine interacts with the glycine site of the NMDA receptor: Electrophysiological studies of dopamine neurons in the rat ventral tegmental area.
        Life Sci. 2008; 83: 170-175
        • Javitt D.C.
        • Duncan L.
        • Balla A.
        • Sershen H.
        Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: Implications for mechanisms of action.
        Mol Psychiatry. 2005; 10: 275-287
        • Lin C.H.
        • Lane H.Y.
        • Tsai G.E.
        Glutamate signaling in the pathophysiology and therapy of schizophrenia.
        Pharmacol Biochem Behav. 2012; 100: 665-677
        • Heresco-Levy U.
        Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
        Expert Opin Emerg Drugs. 2005; 10: 827-844
        • Coyle J.T.
        NMDA receptor and schizophrenia: A brief history.
        Schizophr Bull. 2012; 38: 920-926
        • Javitt D.C.
        • Schoepp D.
        • Kalivas P.W.
        • Volkow N.D.
        • Zarate C.
        • Merchant K.
        • et al.
        Translating glutamate: From pathophysiology to treatment.
        Sci Transl Med. 2011; 3 (102mr102)
        • Krystal J.H.
        • Karper L.P.
        • Seibyl J.P.
        • Freeman G.K.
        • Delaney R.
        • Bremner J.D.
        • et al.
        Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
        Arch Gen Psychiatry. 1994; 51: 199-214
        • Errico F.
        • Mothet J.P.
        • Usiello A.
        D-aspartate: An endogenous NMDA receptor agonist enriched in the developing brain with potential involvement in schizophrenia.
        J Pharm Biomed Anal. 2015; 116: 7-17
        • Hashimoto K.
        Targeting of NMDA receptors in new treatments for schizophrenia.
        Expert Opin Ther Targets. 2014; 18: 1049-1063
        • Fukui K.
        • Miyake Y.
        Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase.
        J Biol Chem. 1992; 267: 18631-18638
        • Vanoni M.A.
        • Cosma A.
        • Mazzeo D.
        • Mattevi A.
        • Todone F.
        • Curti B.
        Limited proteolysis and X-ray crystallography reveal the origin of substrate specificity and of the rate-limiting product release during oxidation of D-amino acids catalyzed by mammalian D-amino acid oxidase.
        Biochemistry. 1997; 36: 5624-5632
        • Sasabe J.
        • Miyoshi Y.
        • Suzuki M.
        • Mita M.
        • Konno R.
        • Matsuoka M.
        • et al.
        D-amino acid oxidase controls motoneuron degeneration through D-serine.
        Proc Natl Acad Sci U S A. 2012; 109: 627-632
        • Madeira C.
        • Freitas M.E.
        • Vargas-Lopes C.
        • Wolosker H.
        • Panizzutti R.
        Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia.
        Schizophr Res. 2008; 101: 76-83
        • Smith S.M.
        • Uslaner J.M.
        • Hutson P.H.
        The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors.
        Open Med Chem J. 2010; 4: 3-9
        • Van den Berghe-Snorek S.
        • Stankovich M.T.
        Thermodynamic control of D-amino acid oxidase by benzoate binding.
        J Biol Chem. 1985; 260: 3373-3379
        • Modi K.K.
        • Roy A.
        • Brahmachari S.
        • Rangasamy S.B.
        • Pahan K.
        Cinnamon and its metabolite sodium benzoate attenuate the activation of p21rac and protect memory and learning in an animal model of Alzheimer's disease.
        PLoS One. 2015; 10e0130398
      1. Joint FAO/WHO Expert Committee on Food Additives (1973): 21 CFR §184.1733-sodium benzoate. Available at: https://www.gpo.gov/fdsys/pkg/CFR-2004-title21-vol3/pdf/CFR-2004-title21-vol3-sec184-1733.pdf. Accessed September 12, 2013.

        • Batshaw M.L.
        • Hyman S.L.
        • Coyle J.T.
        • Robinson M.B.
        • Qureshi I.A.
        • Mellits E.D.
        • et al.
        Effect of sodium benzoate and sodium phenylacetate on brain serotonin turnover in the ornithine transcarbamylase-deficient sparse-fur mouse.
        Pediatr Res. 1988; 23: 368-374
        • Husson M.C.
        • Schiff M.
        • Fouilhoux A.
        • Cano A.
        • Dobbelaere D.
        • Brassier A.
        • et al.
        Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: A multicentre retrospective study.
        Orphanet J Rare Dis. 2016; 11: 127
        • Lane H.Y.
        • Lin C.H.
        • Green M.F.
        • Hellemann G.
        • Huang C.C.
        • Chen P.W.
        • et al.
        Add-on treatment of benzoate for schizophrenia: A randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
        JAMA Psychiatry. 2013; 70: 1267-1275
        • Mattson M.P.
        Glutamate and neurotrophic factors in neuronal plasticity and disease.
        Ann N Y Acad Sci. 2008; 1144: 97-112
        • Tilleux S.
        • Hermans E.
        Neuroinflammation and regulation of glial glutamate uptake in neurological disorders.
        J Neurosci Res. 2007; 85: 2059-2070
        • Lipton S.A.
        • Rosenberg P.A.
        Excitatory amino acids as a final common pathway for neurologic disorders.
        N Engl J Med. 1994; 330: 613-622
        • Kalia L.V.
        • Kalia S.K.
        • Salter M.W.
        NMDA receptors in clinical neurology: Excitatory times ahead.
        Lancet Neurol. 2008; 7: 742-755
        • American Psychiatric Association
        Structured Clinical Interview for DSM-IV.
        American Psychiatric Press, Washington, DC1994
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders, 4th ed.
        American Psychiatric Press, Washington, DC1994
        • Kay S.R.
        • Fiszbein A.
        • Opler L.A.
        The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
        Schizophr Bull. 1987; 13: 261-276
        • Andreasen N.C.
        The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and theoretical foundations.
        Br J Psychiatry Suppl. 1989; 7: 49-58
        • Heinrichs D.W.
        • Hanlon T.E.
        • Carpenter Jr., W.T.
        The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome.
        Schizophr Bull. 1984; 10: 388-398
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Goff D.C.
        • Tsai G.
        • Levitt J.
        • Amico E.
        • Manoach D.
        • Schoenfeld D.A.
        • et al.
        A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
        Arch Gen Psychiatry. 1999; 56: 21-27
        • Green M.F.
        • Nuechterlein K.H.
        • Gold J.M.
        • Barch D.M.
        • Cohen J.
        • Essock S.
        • et al.
        Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria.
        Biol Psychiatry. 2004; 56: 301-307
        • Bartko J.J.
        The intraclass correlation coefficient as a measure of reliability.
        Psychol Rep. 1966; 19: 3-11
        • Simpson G.M.
        • Angus J.W.
        A rating scale for extrapyramidal side effects.
        Acta Psychiatr Scand Suppl. 1970; 212: 11-19
        • Lingjaerde O.
        • Ahlfors U.G.
        • Bech P.
        • Dencker S.J.
        • Elgen K.
        The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.
        Acta Psychiatr Scand Suppl. 1987; 334: 1-100
        • Rosenthal R.
        • Rosnow R.
        Essentials of Behavioral Research: Methods and Data Analysis, 2nd ed.
        McGraw Hill, New York1991
        • Muscatello M.R.
        • Bruno A.
        • De Fazio P.
        • Segura-Garcia C.
        • Pandolfo G.
        • Zoccali R.
        Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine.
        Expert Opin Pharmacother. 2014; 15: 2329-2345
        • Lin C.Y.
        • Liang S.Y.
        • Chang Y.C.
        • Ting S.Y.
        • Kao C.L.
        • Wu Y.H.
        • et al.
        Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
        World J Biol Psychiatry. 2017; 18: 357-368
        • Lane H.Y.
        • Huang C.L.
        • Wu P.L.
        • Liu Y.C.
        • Chang Y.C.
        • Lin P.Y.
        • et al.
        Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
        Biol Psychiatry. 2006; 60: 645-649
        • Tsai G.E.
        • Yang P.
        • Chung L.C.
        • Tsai I.C.
        • Tsai C.W.
        • Coyle J.T.
        D-serine added to clozapine for the treatment of schizophrenia.
        Am J Psychiatry. 1999; 156: 1822-1825
        • Diaz P.
        • Bhaskara S.
        • Dursun S.M.
        • Deakin B.
        Double-blind, placebo-controlled, crossover trial of clozapine plus glycine in refractory schizophrenia negative results.
        J Clin Psychopharmacol. 2005; 25: 277-278
        • Evins A.E.
        • Fitzgerald S.M.
        • Wine L.
        • Rosselli R.
        • Goff D.C.
        Placebo-controlled trial of glycine added to clozapine in schizophrenia.
        Am J Psychiatry. 2000; 157: 826-828
        • Goff D.C.
        • Henderson D.C.
        • Evins A.E.
        • Amico E.
        A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia.
        Biol Psychiatry. 1999; 45: 512-514
        • DeLorenzo R.J.
        • Pal S.
        • Sombati S.
        Prolonged activation of the N-methyl-D-aspartate receptor-Ca2+ transduction pathway causes spontaneous recurrent epileptiform discharges in hippocampal neurons in culture.
        Proc Natl Acad Sci U S A. 1998; 95: 14482-14487
        • Welham J.
        • Stedman T.
        • Clair A.
        Choosing negative symptom instruments: Issues of representation and redundancy.
        Psychiatry Res. 1999; 87: 47-56
        • Juckel G.
        • Morosini P.L.
        The new approach: Psychosocial functioning as a necessary outcome criterion for therapeutic success in schizophrenia.
        Curr Opin Psychiatry. 2008; 21: 630-639
        • Juckel G.
        • Schaub D.
        • Fuchs N.
        • Naumann U.
        • Uhl I.
        • Witthaus H.
        • et al.
        Validation of the Personal and Social Performance (PSP) scale in a German sample of acutely ill patients with schizophrenia.
        Schizophr Res. 2008; 104: 287-293
        • Gardner D.M.
        • Murphy A.L.
        • O'Donnell H.
        • Centorrino F.
        • Baldessarini R.J.
        International consensus study of antipsychotic dosing.
        Am J Psychiatry. 2010; 167: 686-693
        • Lane H.Y.
        • Chang Y.C.
        • Chang W.H.
        • Lin S.K.
        • Tseng Y.T.
        • Jann M.W.
        Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics.
        J Clin Psychiatry. 1999; 60: 36-40
        • Miyamoto S.
        • Jarskog L.F.
        • Fleischhacker W.W.
        New therapeutic approaches for treatment-resistant schizophrenia: A look to the future.
        J Psychiatr Res. 2014; 58: 1-6
        • Taylor D.M.
        • Smith L.
        • Gee S.H.
        • Nielsen J.
        Augmentation of clozapine with a second antipsychotic - A meta-analysis.
        Acta Psychiatr Scand. 2012; 125: 15-24
        • Goff D.C.
        • Leahy L.
        • Berman I.
        • Posever T.
        • Herz L.
        • Leon A.C.
        • et al.
        A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.
        J Clin Psychopharmacol. 2001; 21: 484-487
        • Goff D.C.
        • Lamberti J.S.
        • Leon A.C.
        • Green M.F.
        • Miller A.L.
        • Patel J.
        • et al.
        A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
        Neuropsychopharmacology. 2008; 33: 465-472
        • de Lucena D.
        • Fernandes B.S.
        • Berk M.
        • Dodd S.
        • Medeiros D.W.
        • Pedrini M.
        • et al.
        Improvement of negative and positive symptoms in treatment-refractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
        J Clin Psychiatry. 2009; 70: 1416-1423
        • Potkin S.G.
        • Jin Y.
        • Bunney B.G.
        • Costa J.
        • Gulasekaram B.
        Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
        Am J Psychiatry. 1999; 156: 145-147
        • Heresco-Levy U.
        • Javitt D.C.
        • Ermilov M.
        • Mordel C.
        • Silipo G.
        • Lichtenstein M.
        Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
        Arch Gen Psychiatry. 1999; 56: 29-36
        • Matsuura A.
        • Fujita Y.
        • Iyo M.
        • Hashimoto K.
        Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
        Acta Neuropsychiatr. 2015; 27: 159-167
        • Pahan K.
        Immunomodulation of experimental allergic encephalomyelitis by cinnamon metabolite sodium benzoate.
        Immunopharmacol Immunotoxicol. 2011; 33: 586-593
        • Sershen H.
        • Hashim A.
        • Dunlop D.S.
        • Suckow R.F.
        • Cooper T.B.
        • Javitt D.C.
        Modulating NMDA receptor function with D-amino acid oxidase inhibitors: Understanding functional activity in PCP-treated mouse model.
        Neurochem Res. 2016; 41: 398-408
        • Lu J.M.
        • Gong N.
        • Wang Y.C.
        • Wang Y.X.
        D-Amino acid oxidase-mediated increase in spinal hydrogen peroxide is mainly responsible for formalin-induced tonic pain.
        Br J Pharmacol. 2012; 165: 1941-1955
        • Stegman L.D.
        • Zheng H.
        • Neal E.R.
        • Ben-Yoseph O.
        • Pollegioni L.
        • Pilone M.S.
        • et al.
        Induction of cytotoxic oxidative stress by D-alanine in brain tumor cells expressing Rhodotorula gracilis D-amino acid oxidase: A cancer gene therapy strategy.
        Human Gene Ther. 1998; 9: 185-193
        • Jagannath V.
        • Gerstenberg M.
        • Correll C.U.
        • Walitza S.
        • Grünblatt E.
        A systematic meta-analysis of the association of neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.
        J Neural Transm (Vienna). 2018; 125: 89-102
        • Howard D.M.
        • Adams M.J.
        • Clarke T.K.
        • Wigmore E.M.
        • Zeng Y.
        • Hagenaars S.P.
        • et al.
        Haplotype-based association analysis of general cognitive ability in Generation Scotland, the English Longitudinal Study of Ageing, and UK Biobank.
        Wellcome Open Res. 2017; 2: 61
        • Verrall L.
        • Burnet P.W.
        • Betts J.F.
        • Harrison P.J.
        The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.
        Mol Psychiatry. 2010; 15: 122-137
        • Lin C.H.
        • Chang H.T.
        • Chen Y.J.
        • Huang C.H.
        • Tun R.
        • Tsai G.E.
        • et al.
        Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals.
        Mol Psychiatry. 2014; 19: 636-637
        • Akyol E.S.
        • Albayrak Y.
        • Aksoy N.
        • Sahin B.
        • Beyazyuz M.
        • Kuloglu M.
        • et al.
        Increased serum G72 protein levels in patients with schizophrenia: A potential candidate biomarker.
        Acta Neuropsychiatr. 2017; 29: 80-86
        • Sacchi S.
        • Binelli G.
        • Pollegioni L.
        G72 primate-specific gene: A still enigmatic element in psychiatric disorders.
        Cell Mol Life Sci. 2016; 73: 2029-2039
        • Flatow J.
        • Buckley P.
        • Miller B.J.
        Meta-analysis of oxidative stress in schizophrenia.
        Biol Psychiatry. 2013; 74: 400-409
        • Arabsolghar R.
        • Saberzadeh J.
        • Khodaei F.
        • Borojeni R.A.
        • Khorsand M.
        • Rashedinia M.
        The protective effect of sodium benzoate on aluminum toxicity in PC12 cell line.
        Res Pharm Sci. 2017; 12: 391-400